Severe and refractory hypocalcaemia secondary to osteoblastic bone metastases in bladder signet ring carcinoma
A case report and literature review
Wanling Zeng, MD, MRCP(UK), MMeda*, Du Soon Swee, MBBS, MRCP(UK), FRCP (Edin), FECSMa

Abstract
Rationale: Symptomatic hypocalcaemia is uncommon, occurring in <2% of patients with malignancy. Osteoblastic bone metastasis as a cause of hypocalcaemia is rare and not reported in bladder cancer.

Patient concerns: We report a case of refractory hypocalcaemia in a patient with bladder cancer with extensive osteoblastic bone metastases. A 64-year-old male with a history of signet ring bladder carcinoma with osteoblastic bone metastases presented with severe hypocalcaemia with corrected calcium of 1.64 (2.09–2.46) mmol/L as well as hypomagnesemia and hypophosphatemia. He was previously treated with chemotherapy and immunotherapy. Denosumab was also initiated for the prevention of skeletal-related events.

Diagnoses: Additional investigations showed significantly elevated bone formation markers N-terminal propeptide of type I procollagen and alkaline phosphatase. Chest radiography and computed tomography scan also demonstrated extensive areas of sclerotic bone lesions suggestive of osteoblastic bone metastases. He was diagnosed with severe hypocalcaemia secondary to osteoblastic bone metastases and partly to denosumab, vitamin D deficiency, and hypomagnesemia.

Interventions: He was treated aggressively with calcium and vitamin D replacement.

Outcomes: Despite prolonged intravenous calcium replacement and high doses of oral calcium, cholecalciferol, and calcitriol replacement, he had persistent hypocalcaemia with calcium levels ranging from 1.8 to 1.9 mmol/L. He died 4 months after his admission.

Lessons: Osteoblastic bone metastases lead to an increased influx of calcium and phosphate into the bone leading to hypocalcaemia and should be considered as a differential in severe and refractory hypocalcaemia. It is rare and has not been described in bladder cancer. Precaution should be taken upon the initiation of antiresorptive in patients with osteoblastic bone metastases.

Abbreviations: ALP = alkaline phosphatase, CT = computed tomography, CTX = C-terminal telopeptide of type I collagen, iPTH = intact parathyroid hormone, IV = intravenous, MRI = magnetic resonance imaging, P1NP = N-terminal propeptide of type I procollagen, SREs = skeletal-related events.

Keywords: denosumab, osteoblastic bone metastases, refractory hypocalcaemia, signet ring bladder cancer

1. Introduction
Symptomatic hypocalcaemia, an uncommonly encountered complication of malignancy, was reported in about 1.6% of patients admitted under oncology. The pathophysiology of hypocalcaemia in affected patients is often multifactorial, of which osteoblastic bone metastasis is a rare cause. Bone metastasis can be classified as osteolytic, osteoblastic, or mixed and can lead to dysregulation of bone metabolism. Osteoblastic bone metastasis contributing to hypocalcaemia is typically described in prostate and breast cancer and rarely in gastric and salivary carcinoma. To date, hypocalcaemia resulting from osteoblastic bone metastases in bladder cancer has not been reported. Bone is a common site of metastasis and can occur in 40% of bladder cancer. Signet ring cell carcinoma of the bladder is a rare and aggressive variant of adenocarcinoma. We report a case of refractory severe hypocalcaemia secondary to osteoblastic bone metastases in a patient with metastatic signet ring cell carcinoma of the bladder. In view of the paucity of published information, a
review of literature on the cases of osteoblastic bone metastases induced hypocalcaemia to further characterise this rare condition is also presented.

2. Case presentation

A 64-year-old male initially admitted for ex- percutaneous nephrostomy site leakage was referred to our department for severe hypocalcaemia with corrected nonionized calcium of 1.64 mmol/L. He had a significant oncological history of metastatic signet ring bladder cancer diagnosed 1 year ago with rapid disease progression despite systemic treatment with chemotherapy and immunotherapy. At diagnosis, he was started on subcutaneous denosumab (Xgeva) 120 mg every 3 months for the prevention of skeletal-related events (SREs) in view of his extensive bone metastases in the sacrum and pelvis. He had received 3 doses of denosumab in total with the last dose being administered 3 months prior to his admission. On assessment, he had no symptoms of hypocalcaemia, such as perioral numbness and carpopedal spasm. He had no previous neck surgery or radiation and no significant family history of hypocalcaemia to suggest parathyroid gland injury or genetic disorder, respectively. He did not take any long-term supplements or complementary medicine. On physical examination, he had no neck scar with negative Chvostek’s and Trouseau’s sign and systemic review was unremarkable.

On admission, the biochemical investigations revealed severe hypocalcaemia (corrected nonionized calcium 1.64 [2.09–2.46] mmol/L with hypomagnesemia and hypophosphatemia. Intact parathyroid hormone (iPTH) level was markedly elevated in response to severe hypocalcaemia and vitamin D deficiency and that helped to exclude hypoparathyroidism (Table 1). He had no calcium measurement prior to admission for comparison. His electrocardiogram showed sinus tachycardia with no QTC prolongation. Chest radiography and computed tomography (CT) scan showed extensive areas of sclerosis in the bones suggestive of osteoblastic bone metastases (Fig. 1). Evaluation of the bone turnover markers demonstrated significant elevation of bone formation markers N-terminal propeptide of type I procollagen (P1NP) and alkaline phosphatase (ALP) at >18-fold and >13-fold respectively and comparative suppression of bone resorptive marker C-terminal telopeptide of type I collagen (CTX) which is indicative of a predominant osteoblastic activity resulting in disproportionate calcium influx into the bone (Table 1).

His hypocalcaemia was contributed primarily by the underlying osteoblastic bone metastases and partially by the denosumab therapy, hypomagnesemia, and vitamin D deficiency. Denosumab was withheld and he was started on intravenous (IV) calcium gluconate boluses 2 to 5 cycles daily with concurrent oral replacement with calcium carbonate tablets 2.5 g 3 times daily, calcitriol 0.5 μg twice daily, cholecalciferol 50 000 IU once weekly and with magnesium replacement. Despite daily IV calcium replacement, oral calcium replacement with dose increment to 3.75 g 5 times daily, oral calcitriol replacement with dose increment to 1 μg 3 times daily, he had refractory and persistent hypocalcaemia with his calcium level ranging from 1.7 to 1.9 mmol/L (Fig. 2). He required a total of 16 days of IV calcium replacement with concurrent oral calcium and vitamin D replacement to maintain his corrected calcium at 1.92 mmol/L. He was discharged but was readmitted for symptomatic hypocalcaemia, symptomatic anaemia, fluid overload as well as pneumonia. He remained hypocalcaemic even after stopping denosumab for 6 months and he required high doses of calcium carbonate 1.25 g 4 times daily, calcitriol 1 μg 4 times daily, and cholecalciferol 25000 IU every 2 weekly to maintain his corrected calcium between 1.9 and 2.1 mmol/L. In view of the aggressive nature of the underlying metastatic bladder cancer and rapidly deteriorating functional status, he was deemed not a suitable candidate for systemic chemotherapy or radionuclide therapy. He was referred to the palliative team for comfort care and he eventually succumbed to the metastatic cancer 16 months after his diagnosis.

3. Discussion

Hypocalcaemia is a common complication in malignancy, however, hypocalcaemia is less frequently reported and can occur in <2% of hospitalised patients. Hypocalcaemia in malignant disease can be secondary to various aetiologies categorised into nutritional deficiencies such as vitamin D deficiency, hypomagnesemia, malabsorption; secondary to treatments as osteoblastic bone lesions such as chemotherapy or antiresorptive; or secondary to osteoblastic bone metastasis, hypoparathyroidism, tumour lysis syndrome, or acute illness.

A comprehensive literature review of case reports on hypocalcaemia secondary to osteoblastic bone metastases published in year 1982 to 2020 were summarised in Table 2. A total of 21 cases were included and the age, gender, underlying primary malignancy, other contributing factors of hypocalcaemia and treatment modalities were reviewed. Prostate carcinoma was the most common malignancy with 12 cases followed by breast carcinoma (6 cases), gastric carcinoma (2 cases), and salivary gland carcinoma (1 case). The ages of the patients range from 37 to 88 years old. We found that in addition to osteoblastic bone metastases, concomitant vitamin D deficiency or relative hypoparathyroidism are common contributing factors of hypocalcaemia. We did not include patients on antiresorptive treatments as they were well-established contributors of refractory hypocalcaemia even in the absence of osteoblastic bone metastases.

3.1. Risk factors contributing to the development of hypocalcaemia in malignancy

Hypocalcaemia secondary to osteoblastic bone metastases has been a well-established complication in prostate and breast cancer. It has been reported in gastric and salivary carcinoma but not in bladder cancer. Skeleton is one of the most frequent sites of metastasis after lung and liver and the relative incidence of bone metastasis in bladder cancer is 40%. Bone metastases increase the risks of morbidity and SREs such as hypercalcemia, bone pain, pathological fractures, cord compression, and bone marrow dysfunction and patients with bladder cancer and bone metastases generally have poorer prognosis with a median survival of 6 to 9 months. The bone metastasis found in bladder cancer can be classified as osteoblastic, osteolytic, or mixed. Metastasis altered bone homeostasis by decoupling the balance between bone resorption by osteoclasts and bone formation by osteoblasts. The type of bone metastasis depends on the activation and inhibition of osteoclasts and osteoblasts. Osteolytic
bone metastasis is mediated by osteoclasts resulting in bone destruction and resorption. Major mediators of osteoclast activity include parathyroid hormone-related protein, bone-derived transforming growth factor-β, and receptor activator of nuclear factor-kB ligand. On the other hand, the exact pathogenesis of osteoblastic bone metastasis is still poorly elucidated. Osteoblastic bone lesions have been postulated to be stimulated by osteoblast growth factors such as platelet-derived growth factor, insulin-like growth factors, adrenomedullin, transforming growth factor, bone morphogenic proteins, and endothelin-1. The increased osteoblastic activity acts as a sink trap resulting in an increased uptake and utilisation of calcium leading to hypocalcaemia.

Classically, the biochemical investigations reveal low serum calcium, normal or low serum phosphate, low 25-hydroxyvitamin D, elevated iPTH, ALP, and other bone turnover markers. In terms of imaging, plain radiography, CT, magnetic resonance imaging (MRI), and bone scintigraphy are commonly utilised for the evaluation of bone metastases. Plain radiography is fast and inexpensive but has a low sensitivity of 44% to 50% while CT, MRI, and bone scintigraphy have better sensitivity of 74%, 95%, and 78%, respectively. Bone scintigraphy allows for evaluation of the whole skeleton and MRI is the imaging modality of choice for detection of metastatic lesion in the bone marrow as well as to assess for cord compression. In our patient, his biochemical abnormalities of hypocalcaemia, hypophosphatemia, raised iPTH and bone formation markers ALP and P1NP were typical of osteoblastic bone metastases. In addition, osteoblastic bone metastases were also reported on the chest radiography and CT imaging.

Figure 1. Chest radiography (CXR) and computed tomography (CT) scan showing extensive osteoblastic bone metastases (blue arrows).

Figure 2. Calcium trend during the patient’s admission on calcium and vitamin D replacement.
Not all patients with osteoblastic bone metastases develop hypocalcaemia and a previous study reported an incidence of at least 13% in patients with prostate cancer.\[^{31}\] Antiresorptive therapies such as bisphosphonates and denosumab which are traditionally used in the management of bone metastases are primarily osteoclast-targeted, with indirect and proportionately less effects on inhibition of osteoblasts.\[^{32}\] Antiresorptive agents have proven to be beneficial in lowering the risk of SREs,\[^{33,34}\] however, it can lead to severe and refractory hypocalcaemia especially in patients with chronic kidney disease, vitamin D deficiency, hypomagnesemia, or the presence of osteoblastic bone metastases.\[^{35–37}\] Patients with bone metastasis that is predominantly and aggressively osteoblastic have markedly increased risk of developing hypocalcaemia following antiresorptive treatment, as that further decouples the osteoclast-osteoblast activity. In the presence of hypocalcaemia, iPTH increases as a compensatory mechanism to increase osteoclastic bone resorption and thus maintaining normocalcaemia. The antiresorptive effect of denosumab or bisphosphonates inhibits this process resulting in unopposed sequestration of calcium into the skeleton leading to severe and protracted hypocalcaemia even with high doses of calcium replacement. Furthermore, it has been postulated that bisphosphonate at low doses might lead to osteoblast proliferation and thus the development of hypocalcaemia.\[^{38}\] Hypocalcaemia occurred more frequently (9.6%–13% in denosumab vs 3.9%–6% in zoledronic acid) and earlier in patients treated with denosumab compared to bisphosphonate such as zoledronic acid.\[^{36,38}\] The usage of vitamin D and calcium replacement has been shown to lower the risk of hypocalcaemia by 40%.\[^{36}\]

Both hypomagnesemia and vitamin D deficiency can also contribute to the development of hypocalcaemia. Hypomagnesemia results in decreased PTH secretion as well as resistance to PTH action at the receptor.\[^{7,37}\] Vitamin D deficiency reduces gastrointestinal calcium absorption as well as kidney reabsorption of calcium.\[^{7,37}\] Vitamin D deficiency and hypomagnesemia is highly prevalent in patients with malignancy which can be secondary to medications and malnutrition. Based on the previously published case reports (Table 2), vitamin D deficiency is commonly observed in patients with

\[\text{Table 2} \]
Summary for case reports of hypocalcaemia in osteoblastic bone metastases.

| Year | Author | Age/gender | Cancer site/histology | Other contributing factors | Treatment |
|------|--------|------------|-----------------------|---------------------------|-----------|
| 2006 | Dawson et al\[^{5}\] | 70 yo/M | Salivary gland/undifferentiated | Relative hypoparathyroidism | Calcium and Vit D replacement, Chemotherapy, Radiotherapy |
| 2017 | Okazaki et al\[^{4}\] | 60 yo/F | Gastric/adeno carcinoma | Hx of total thyroidectomy | Calcium and Vit D replacement, Chemotherapy |
| 2020 | Sakai et al\[^{3}\] | 87 yo/M | Gastric/signet ring cell | Nil | Not known |
| 1982 | Unger et al\[^{8}\] | 85 yo/F | Breast | Relative hypoparathyroidism | Not known |
| 1988 | Hermus et al\[^{9}\] | 55 yo/F | Breast/poorly differentiated | Relative hypoparathyroidism | Calcium and Vit D replacement, Chemotherapy |
| 1989 | Bouvier et al\[^{10}\] | 39 yo/F | Breast | Relative hypoparathyroidism | Calcium and Vit D replacement, Chemotherapy |
| 1994 | Wiegand et al\[^{11}\] | 81 yo/F | Breast | Not known | Not known |
| 2003 | Bengkamp et al\[^{12}\] | 37 yo/F | Breast | Relative hypoparathyroidism | Calcium and Vit D replacement, Chemotherapy |
| 2015 | Farolfi et al\[^{13}\] | 67 yo/F | Breast | Relative hypoparathyroidism | Calcium and Vit D replacement, Chemotherapy |
| 1981 | Smallridge et al\[^{14}\] | 61 yo/M | Prostate/Adenocarcinoma | Nil | Ca replacement, Parathyroid extract, Hormonal treatment |
| 1988 | Kukreja et al\[^{15}\] | 88 yo/M | Prostate/Adenocarcinoma | Relative hypoparathyroidism | Calcium and Vit D replacement, Hormonal treatment |
| 1995 | Szentirmai et al\[^{16}\] | 82 yo/M | Prostate/Adenocarcinoma | Vit D deficiency, CKD | Not known |
| 2000 | Lim et al\[^{17}\] | 80 yo/M | Prostate | Unknown | Vit D resistance | Calcium and Vit D replacement |
| 2005 | Fokkema et al\[^{18}\] | 67 yo/M | Prostate/Adenocarcinoma | Vit D deficiency | Calcium and Vit D replacement, Androgen deprivation therapy |
| 2008 | Yener et al\[^{19}\] | 70 yo/M | Prostate/Adenocarcinoma | Vit D deficiency | Calcium and Vit D replacement, Androgen deprivation therapy |
| 2008 | Pusulari et al\[^{20}\] | 65 yo/M | Prostate | Unknown | Nil | Not known |
| 2015 | Rizzo et al\[^{21}\] | 72 yo/M | Prostate | Vit D deficiency | Calcium and Vit D replacement, Androgen deprivation therapy |
| 2017 | Gebara et al\[^{22}\] | 71 yo/M | Prostate/Adenocarcinoma | Vit D deficiency | Calcium and Vit D replacement, Steroid |
| 2017 | Diéguez et al\[^{23}\] | 84 yo/M | Prostate/Adenocarcinoma | Vit D deficiency | Calcium and Vit D replacement, Androgen deprivation therapy |
| 2018 | Garfa et al\[^{24}\] | 50 yo/M | Prostate | Unknown | Vit D deficiency | Calcium and Vit D replacement, Radium\[^{25}\] dichloride |
| 2020 | Drekolas et al\[^{26}\] | 61 yo/M | Prostate/Adenocarcinoma | Nil | Calcium and Vit D replacement, Chemotherapy and radiotherapy, IV steroid |

CKD = chronic kidney disease, Hx = history, IV = intravenous, Vit D = vitamin D, yo = years old.
hypocalcaemia in malignancy. In addition, vitamin D deficiency increases the risk of hypocalcaemia in patients treated with antiresorptive agent. As such, vitamin D and calcium levels should be routinely checked and replaced before the commencement of antiresorptive therapy which was not the case in our patient.

Relative hypoparathyroidism was found to be another factor that can aggravate hypocalcaemia. The proposed mechanisms of relative hypoparathyroidism were that of tissue destruction by tumour infiltration, radiation, postsurgical or secondary to autoimmune causes however no definite cause was found in most cases.[9,11–13] Parathyroid metastases detected postmortem was reported in 6% to 12% of the oncologic patients.[12] Interestingly, patients with breast cancer that developed hypocalcaemia were more likely to have relative hypoparathyroidism with inappropriately normal serum iPTH in relation to the severe hypocalcaemia, compared to patients with prostate cancer and it might be related to their history of radiation treatment (Table 2).

While the history of denosumab therapy, hypomagnesemia and vitamin D deficiency in our patient could contribute, in part, to the development of the hypocalcaemia, the clinical and biochemical features were, however, strongly suggestive of an osteoblastic process as the leading cause. Firstly, it is unusual for the hypocalcaemia to be evident only at 3 months after his 3rd dose of denosumab and to be persistent for 6 months after his last dose of denosumab. Denosumab has a mean half-life of 29 days and it suppresses the osteoclast activity maximally at approximately 2 weeks following its administration.[17] Patients with prostate cancer treated with denosumab were reported to develop hypocalcaemia at a median of 16 days (range 4–35).[17] Secondly, the pattern of his bone turnover markers was unlike that of typical postdenosumab effect, where both bone formation and resorption markers are expected to decrease.[12] Instead, in our patient, the bone formation markers P1NP and ALP were significantly elevated, which was markedly discordant to the suppressed CTX. Therefore, profound uncoupling of bone remodelling processes due to direct tumoral effect should be considered and this disturbance of coupling depends on the interaction between the microenvironment and the bone. Tumour cell-derived factors in the bone environment are capable of inducing osteoblast-mediated bone formation as well as suppressing osteoclast-mediated bone resorption.[39]

3.2. Utility of bone turnover markers in bone metastases

In bone metastases, dysregulation of bone resorption and bone formation results in the generation of distinct biochemical markers which can be classified into bone formation markers and bone resorption markers. Bone formation markers commonly used in clinical and research setting include bone-specific ALP, osteocalcin, P1NP while bone resorption markers include pyridinoline, deoxypyridinoline, aminoterminal crosslinked telopeptide of type I collagen, CTX, and carboxy-terminal crosslinked telopeptides of collagen type I.[40] Bone turnover markers may provide insight into the state of bone remodelling, allow for prognostication of disease as well as evaluation of treatment response.[40,41] Bone metastases stimulate bone remodelling and bone formation markers are elevated while bone resorption markers can be suppressed or elevated in osteoblastic metastases.[39,40,41] The bone turnover profile in our patient reflected the dominant osteoblastic nature of the bone metastases. As such, these markers could be informative on the relative osteoblastic to osteoclastic activity in patients with sclerotic bone metastases. This may predict which patients will benefit from antiresorptive therapy or are at risk of treatment-induced hypocalcaemia, so that the choice of antiresorptive agent (denosumab versus bisphosphonate), calcium and vitamin D supplementation, as well as biochemical monitoring could be personalised to optimise treatment safety.

3.3. Treatment of hypocalcaemia in malignancy

There is no predefined guideline specific to the management of hypocalcaemia in osteoblastic bone metastases due to the rarity of this entity and initial treatment is similar to that of hypocalcaemia from other causes. In acute symptomatic hypocalcaemia, IV calcium gluconate 10 mL of 10% solution can be given as boluses followed by IV calcium infusion at a rate of 0.5 to 2 mg elemental calcium/kg/hour.[43] Concomitant oral calcium, vitamin D, and calcitriol should be administered, and magnesium should be replaced. Frequent monitoring of symptoms, serum calcium measurements, and adjustment of the calcium and vitamin D replacements are the mainstay of management. However, in hypocalcaemia secondary to osteoblastic bone metastases, high doses of calcium, vitamin D, and calcitriol replacement are often needed as the hypocalcaemia is usually severe and refractory with some cases requiring prolonged IV calcium infusion.[2,12] Treatment of the underlying cancer and bone metastases with chemotherapy have been shown to improve the hypocalcaemia and reduce the requirement of calcium and vitamin D supplementation.[6,44] Radionuclide therapy such as radium-223 dichloride and radioactive samarium used commonly for pain control due to bone metastasis has been described in case reports to normalise the serum calcium level.[24,43] Glucocorticoid can result in suppression of bone formation through its action on the osteoclasts and osteoblasts.[46] It has been used for the management of hypocalcaemia with mixed response.[22,23] In our patient, he remained hypocalcaemic despite 2 weeks of IV calcium infusion in addition to high doses of calcium, vitamin D, and calcitriol replacement. Unfortunately, he was not a candidate for chemotherapy or radionuclide therapy due to his poor prognosis and functional status.

4. Conclusion

In conclusion, osteoblastic bone metastases lead to an increased influx of calcium and phosphate into the bone resulting in hypocalcaemia. Severe refractory hypocalcaemia is unusual even in patients with osteoblastic bone metastases and have been reported in prostate, breast, gastric and salivary cancer. To our knowledge, no cases of hypocalcaemia secondary to osteoblastic bone metastases in bladder cancer have ever been reported. This case illustrates the importance of recognising osteoblastic metastasis as a differential in protracted and severe hypocalcaemia in malignancy. It also highlights the importance of vitamin D repletion as well as serum calcium monitoring with the administration of antiresorptive agent especially in patients with osteoblastic bone metastases. Future study could evaluate the utility of bone turnover markers in predicting the benefits and risks of initiating antiresorptive agent in this group of patients.

Author contributions

Conceptualization: Wanling Zeng, Du Soon Swee.
Data curation: Wanling Zeng, Du Soon Swee.
Writing—original draft: Wanling Zeng.
Writing—review and editing: Wanling Zeng, Du Soon Swee.

References

[1] Blomqvist CP. A hospital survey of hypocalcaemia in patients with malignant disease. Acta Med Scand. 2009;220:167–73.
[2] Alfaro Riveros H, Almodóvar LQ, Farriols Danés C, et al. Hungry bone syndrome: persistent hypocalcaemia related to osteoblastic bone metastases of prostate cancer. J Palliat Med. 2013;16:1496–7.

www.md-journal.com
Drekoulas D, Gonuguntla K, Gadela NV, et al. A rare case of severe sequestrational hypocalcemia in patient with metastatic prostate cancer. Chest. 2020;158:A842–3.

Wood SL, Brown JE. Personal medicine and bone metastases: biomarkers, micro-RNAs and bone metastases. Cancers. 2020;12:2109.

Ho JW, Sundar S. Prolonged hypocalcemia after Zoledronic Acid in a patient with metastatic prostate carcinoma: did Zoledronic Acid trigger osteoblastic activity and avid calcium uptake? Clin Genitourin Cancer. 2012;10:50–3.

Clézardin P, Coleman R, Puppo M, et al. Bone metastasis: mechanisms, therapies, and biomarkers. Physiol Rev. 2021;101:797–855.

Ferreira A, Alho I, Casimiro S, et al. Bone remodeling markers and bone metastases: From cancer research to clinical implications. BoneKEy Rep. 2015;4:668.

Logothetis CJ, Lin SH. Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer. 2005;5:21–8.

Kassi E, Kapsali I, Kokkinos M, et al. Treatment of severe hypocalcemia due to osteoblastic metastases in a patient with post-thyroidal hormone-refractory prostate cancer. JNCI J Natl Cancer Inst. 2011;377:813–22.

Rizzo C, Vella S, Cachia MJ. Refractory hypocalcaemia complicating metastatic prostatic carcinoma. BMJ Case Rep. 2015;2015:bcr2015210005.

Gebara N, Beaini C, Karak FE, et al. Refractory hypocalcemia associated with extensive osteoblastic metastases in a patient with prostate cancer. Neth J Med. 2005;63:34–7.

Yener S, Demir O, Ozdogan O, et al. Severe hypocalcemia because of osteoblastic prostate carcinoma metastases: Letters. Int J Clin Pract. 2008;62:1630–1.

Guise TA, Mohammad KS, Clines G, et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases: fig. 1. Clin Cancer Res. 2006;12:6215s–6s.

Messiou C, Cook G, deSouza NM. Imaging metastatic bone disease from carcinoma of the prostate. Br J Cancer. 2009;101:1223–5.

Riancho JA, Arjona R, Valle R, et al. The clinical spectrum of hypercalcemia associated with bone metastases. J Intern Med. 1989;226:449–52.

Eastell R, Christiansen C, Grauer A, et al. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res. 2011;26:530–7.

Saad F, Gleason DM, Murray R, et al. Long-term efficacy of Zoledronic Acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. JNCI J Natl Cancer Inst. 2004;96:879–82.

Fizzi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377:813–22.

Mccabe RW, Johnson JT. Severe, prolonged, denosumab-induced hypocalcemia with recovery after 111 days of high-dose calcium supplementation. AACE Clin Case Rep. 2019;5:e82–5.

Bodl JJ, Bone HG, de Boer RH, et al. Hypocalcaemia in patients with metastatic bone disease treated with denosumab. Eur J Cancer. 2015;51:1812–21.

Lau L, Clift ERS, Wong V, et al. Hypocalcaemia following denosumab in prostate cancer: a clinical review. Clin Endocrinol (Oxf). 2020;92:495–502.

Kassi E, Kapsali I, Kokkinos M, et al. Case report: clinical hypocalcemia: the Endocrine Conference of the Alton Ochsner Medical Institutions and Tulane University-Medical Center. Am J Med Sci. 1994;308:255–8.

Okazaki J, Muguruma N, Kitamura S, et al. Paraneoplastic hypocalcemia associated with prostate cancer successfully treated with radium therapy. BMJ Clin Case Rep. 2017;2017:bcr2017-219354.

O’Brien CA, Jia D, Plotkin LI, et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology. 2004;145:1835–41.